Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Therapeutics Inc.

Kepler Capital analyst Laurent Daure maintained a Buy rating on Capgemini SE on December 10 and set a price target of €195.00. The company’s shares...

Capgemini SE (0HAZ): New Buy Recommendation for This Technology Giant

Cullinan Management ( ($CGEM) ) has issued an announcement. On December 8, 2025, Cullinan Therapeutics presented updated clinical data from its Pha...

Cullinan Therapeutics Presents Promising CLN-049 Data

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Cullinan Management, with a price target of $38.00. According ...

Market Cap	$442.48M	P/E Ratio	N/A
52W High	$13.60	52W Low	$5.68
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	78.8%
Overall Score	52	Value Score	60
Quality Score	31	Technical Score	66

EPS Current Est	$-3.47	EPS Next Est	$-3.28
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CGEM	$11.92	-3.72%	937.43K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CGEM	$11.92	-3.7%	937.43K
3
4
5
6

CGEM

CGEM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Cullinan Therapeutics Inc. Data in Excel

Get Cullinan Therapeutics Inc. Data in Excel